3D-QSAR pharmacophore modeling and in silico screening of new Bcl-xl inhibitors

Area of Science:

• Medicinal Chemistry
• Computational Drug Design
• Oncology

Background:

• Bcl-2 protein family members are crucial in cancer progression, promoting tumor cell survival and chemoresistance by inhibiting apoptosis.
• Targeting Bcl-xl, a key member of the Bcl-2 family, is a promising strategy for novel cancer therapeutics.

Purpose of the Study:

• To develop a 3D-QSAR pharmacophore model for biarylacylsulfonamides to understand structural determinants of Bcl-xl inhibition.
• To utilize the validated model for virtual screening of a drug-like database to identify novel Bcl-xl inhibitor scaffolds.

Main Methods:

• A 3D-QSAR pharmacophore model was constructed using a dataset of 42 biarylacylsulfonamides.
• The model was employed as a 3D search query against the ZINC drug-like database.
• Docking studies were performed on identified hits to assess their binding interactions with the Bcl-xl receptor.

Main Results:

• Key structural features contributing to inhibitory activity were identified, including aromaticity, negative charge, and hydrogen bond acceptor effects.
• Virtual screening yielded six potential novel scaffolds with predicted Bcl-xl inhibitory activity.
• Docking simulations confirmed the ability of these compounds to interact with the Bcl-xl receptor.

Conclusions:

• The developed 3D-QSAR pharmacophore model effectively identifies structural requirements for Bcl-xl inhibition.
• Novel small molecule inhibitors targeting Bcl-xl were discovered through virtual screening.
• The identified compounds represent promising candidates for further preclinical evaluation in cancer therapy.